US equities
|
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
NBIS
$158.74
▲+0.00%
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
NBIS
$158.74
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Graphite Bio, Inc. - Common Stock
(NQ:
GRPH
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Graphite Bio, Inc. - Common Stock
< Previous
1
2
Next >
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
March 08, 2024
From
Graphite Bio, Inc.
Via
Business Wire
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
February 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
December 11, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EngageSmart, Inc. (NYSE – ESMT), WaveDancer, Inc. (Nasdaq – WAVD), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EngageSmart, Inc. (NYSE – ESMT), WaveDancer, Inc. (Nasdaq – WAVD), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR),
November 27, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
November 17, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
November 16, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
November 15, 2023
From
Halper Sadeh LLC
Via
Business Wire
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
November 15, 2023
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Departure of Chief Financial Officer
June 23, 2023
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
March 20, 2023
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
February 22, 2023
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
January 05, 2023
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
December 11, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
November 21, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 09, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
November 03, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
October 11, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
August 11, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
August 11, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in Jefferies Healthcare Conference
June 01, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio, Inc. (NASDAQ:GRPH) Investor Alert: Investigation over Potential Wrongdoing
↗
May 26, 2022
San Diego, CA -- (SBWIRE) -- 05/26/2022 -- An investigation on behalf of current long-term investors in shares of Graphite Bio, Inc. (NASDAQ:GRPH) was announced over potential breaches of fiduciary...
Via
SBWire
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
May 16, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
May 12, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in Upcoming Investor Conferences
May 04, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
May 03, 2022
From
Graphite Bio, Inc.
Via
Business Wire
Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program
May 02, 2022
From
Graphite Bio, Inc.
Via
Business Wire
NASDAQ:GRPH Shareholder Notice: Investigation over Possible Securities Laws Violations by Graphite Bio, Inc.
↗
April 13, 2022
San Diego, CA -- (SBWIRE) -- 04/13/2022 -- Graphite Bio, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
< Previous
1
2
Next >
